Eventide Asset Management LLC Takes $11.64 Million Position in Silence Therapeutics plc (NASDAQ:SLN)

Eventide Asset Management LLC purchased a new stake in shares of Silence Therapeutics plc (NASDAQ:SLN) during the third quarter, HoldingsChannel reports. The institutional investor purchased 640,000 shares of the company’s stock, valued at approximately $11,635,000.

A number of other institutional investors have also recently made changes to their positions in SLN. Values First Advisors Inc. bought a new position in Silence Therapeutics during the third quarter valued at approximately $56,000. Quarry LP bought a new position in Silence Therapeutics during the second quarter valued at approximately $114,000. Verition Fund Management LLC bought a new position in Silence Therapeutics during the third quarter valued at approximately $207,000. Custom Index Systems LLC bought a new position in Silence Therapeutics during the second quarter valued at approximately $282,000. Finally, The Manufacturers Life Insurance Company bought a new position in Silence Therapeutics during the third quarter valued at approximately $318,000. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on SLN shares. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a research report on Friday, November 15th. Chardan Capital reiterated a “buy” rating and issued a $55.00 price target on shares of Silence Therapeutics in a research report on Thursday, November 14th. Jefferies Financial Group started coverage on shares of Silence Therapeutics in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price target on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $49.00 price target on shares of Silence Therapeutics in a research report on Tuesday, October 8th. Finally, William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $57.20.

Silence Therapeutics Stock Performance

Shares of SLN stock opened at $7.67 on Friday. Silence Therapeutics plc has a one year low of $5.81 and a one year high of $27.72. The company’s fifty day moving average price is $16.25 and its 200-day moving average price is $18.34.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.